Phase 1 drugs - what are they?

A little background:

A close friend was diagnosed with liver cancer of unknown origin. He struggled through a round of chemotherapy, and was declared “cancer free.” Mabe 4 months later, he was having stomach pains, so he went back to the doctor. The cancer was back in his liver, and his lungs as well. :frowning: :frowning:

He’s now about 1/2 way through the second round of chemo, and a cat scan showed that the cancer got worse.

So, our friend is going out of town this week to meet with some doctors who may put him in a study with “phase 1 drugs.”

What are phase 1 drugs? Does the fact that he’s doing this mean that he’s given up on conventional measures?

Phase 1 studies test a potential new drug with a small number of volunteers for best dosage and potential side effects. They are the first tests of this drug on (usually healthy, but sometimes afflicted with the illness/disease the drug is meant for) humans. The next phases continue on from there, testing a drug with known side effects, or testing its effectiveness in comparison to commonly used drugs.

Basically, yes.

Here is an explanation of the different phases from http://irb.chw.org/Education/Phases%20of%20Trials.pdf:

PHASE 1, 2, 3, 4 DRUG TRIALS: DIFFERENT STAGES OF TESTING DRUGS IN HUMANS,
FROM FIRST APPLICATION IN HUMANS (PHASE 1) THROUGH LIMITED AND BROAD
CLINICAL TESTS (PHASE 3), TO POST-MARKETING STUDIES (PHASE 4).
Phase 1 Drug Trial
Phase 1 trials include the initial introduction of an investigation new drug into humans. These studies are
typically conducted with healthy volunteers; sometimes, where the drug is intended for use in patients with a
particular disease, however, such patients may participate as subjects. Phase 1 trials are designed to determine
the metabolic and pharmacological actions of the drug in humans, the side effects associated with increasing
doses (to establish a safe dose range), and, if possible, to gain early evidence of effectiveness; they are
typically closely monitored. The ultimate goal of Phase 1 trials is to obtain sufficient information about the
drug’s pharmacokinetics and pharmacological effects to permit the design of well-controlled, sufficiently valid
Phase 2 studies. Other examples of Phase 1 studies include studies of drug metabolism, structure-activity
relationships, and mechanisms of actions in humans, as well as studies in which investigational drugs are used
as research tools to explore biological phenomena or disease processes. The total number of subjects involved
in Phase 1 investigations is generally in the range of 20-80.
Phase 2 Drug Trial
Phase 2 trials include controlled clinical studies conducted to evaluate the drug’s effectiveness for a particular
indication in patients with the disease or condition under study, and to determine the common short-term side
effects and risks associated with the drug. These studies are typically well-controlled, closely monitored, and
conducted with a relatively small number of patients, usually involving no more than several hundred subjects.
Phase 3 Drug Trial
Phase 3 trials involve the administration of a new drug to a larger number of patients in different clinical
settings to determine its safety, effectiveness, and appropriate dosage. They are performed after preliminary
evidence of effectiveness has been obtained, and are intended to gather necessary additional information about
effectiveness and safety for evaluating the overall benefit-risk relationship of the drug, and to provide an
adequate basis for physician labeling. In Phase 3 studies, the drug is used the way it would be administered
when marketed. When these studies are completed and the sponsor believes that the drug is safe and effective
under specific conditions, the sponsor applies to FDA for approval to market the drug. Phase 3 trials usually
involve several hundred to several thousand patient-subjects.
Phase 4 Drug Trial
Concurrent with marketing approval, FDA may seek agreement from the sponsor to conduct certain post-marketing
(Phase 4) studies to delineate additional information about the drug’s risks, benefits, and optimal use.
These studies could include, but would not be limited to, studying different doses or schedules of administration
than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or
use of the drug over a longer period of time [21 CFR §312.85].

Here’s the scoop as I understand it, in layman’s terms. I used to work at a company called Covance (though NOT in a scientific capacity). Covance conducts clinical trials, as well as other laboratory contract research on foods, drugs, and commercial commercial proucts in a number of areas.

First, the DRUG is not Phase I, the TRIAL is Phase I. ALL drugs are Phase I at some point. And as those above pointed out, it’s about establishing safe dosages.

The DANGEROUS element of this is born out by it’s more informal name, toxicity testing. The may be tested by having groups of volunteers receive different, but consistent, dosages; or by gradually increasing the dosage of volunteers until physiological monitoring reveals adverse, or bordering on adverse, physiological reactions. Unfortunately, sometimes these adverse reactions occur immediately, or very quickly, and people die. The pool for these trials is drawn primarily from two sources: healthy volunteers, usually being paid to participate, are the overwhelming bulk of participants for most drugs. For some drugs being tested with an eye toward eventual treatment of very serious or fatal diseases such as cancer, the pool is expanded to include the most seriously ill of the sufferers of that disease.

I hope you will NOT rely on my word alone for what I say next, because I am NOT medically trained. Please, if someone has some knowledge contrary to my opinion below, tell Knighted Vopal Sword that I am full of crap.

I’m sorry to say this is very bad news for your friend. IMO, this means his physician has given up all hope on conventional treatment, and is hoping that a brand new drug, tested on your friend to the limits of his ability to cope with very high doses, may result in what might be termed a “miracle” cure, or remission, or reduction of tumor size or growth rate. I strongly suggest another physician’s opinion before doing this. Phase I trials are inherently the most dangerous, because it is the time that the LEAST is known about the effects of the drug.

“Phase I trials are inherently the most dangerous, because it is the time that the LEAST is known about the effects of the drug.”

True. However, the tradeoff for people suffering from a condition for which there is no known cure is that an experimental drug could cure them! And just because a drug has not yet been shown to be safe does not mean that it isn’t.